Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.
Global stock market chart and trading board - stock photo
Representative image of stock market chart on a glowing particle world map and trading board. (Photo by Yuichiro Chino/Getty Images)
Profile Image
Anan Ashraf·Stocktwits
Updated Sep 26, 2025   |   7:48 AM GMT-04
Share
·
Add us onAdd us on Google

Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price.

While Harrow is a provider of ophthalmic disease management solutions, and Melt Pharmaceuticals is focused on developing non-opioid therapies for sedation during medical procedures.

The acquisition will include Melt’s lead investigational therapy, MELT-300, a sublingually delivered formulation of a fixed dose of Midazolam (3mg) and Ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.

Shares of Harrow jumped 2% in the pre-market session at the time of writing. 
 

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy